Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
Date:10/22/2008

CALGARY, Oct. 22 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Prof. Hardev Pandha of The Royal Surrey Hospital, U.K., entitled "Synergistic Anti-Tumour Activity of Oncolytic Reovirus and Cisplatin in a B16.F10 Mouse Melanoma Model" is scheduled to be presented October 23, 2008 at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The conference is being held in Geneva, Switzerland, from October 21-24, 2008.

In the study, the researchers examined the in vitro and in vivo oncolytic activity of reovirus in combination with cisplatin against a mouse melanoma cell line. The researchers demonstrated that the combined therapy results in significantly increased cell death in vitro compared to either agent alone. In the mouse model, combined therapy suppressed tumour growth and significantly prolonged median survival time. The researchers concluded that the addition of chemotherapeutic agents can significantly enhance the anti-tumour efficacy of reovirus therapy and justify formal clinical evaluation.

This research supports the ongoing U.K. clinical trial examining the combination of REOLYSIN(R) with carboplatin and paclitaxel (REO 011) in patients with advanced cancers. An abstract covering interim results of the trial is expected to be available tomorrow in the Journal of Immunotherapy, the official journal of the International Society for Biological Therapy of Cancer (iSBTc). A poster presentation which will include current results from the trial is scheduled to be presented at the iSBTc conference in San Diego, CA on November 1, 2008.

The poster will be available today on the Oncolytics website at http://www.oncolyticsbiotech.com.

The EORTC-NCI-AACR symposium is held on an annual basis and is jointly organized by the European Organization for Research and Treatment
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...irstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP...Docherty, president and chief operating officer, w...nvestor Summit on November 10, 2009 at 4:00 PM at ...will provide an overview of the Company,s leading ...nterferon Alpha-2b. The slide show portion of the...
(Date:11/6/2009)...-FirstCall/ -- ,, 3Q09 Corporate Highlights:...arketing Authorization to Astellas Pharma Europe L...iness activities Expanded management team to incl...ctor, Commercial Operations Appointed Bradford S....chairman , Upcoming 2009 Milestones: ,...
(Date:11/6/2009)...-- Intarcia Therapeutics, Inc. delivered two prese...uous delivery of exenatide) program for the treatm...s Technology Meeting in San Francisco, CA: ,, (...1/SFTU126LOGO ) ,, Continuous Subcutaneous De...cose, HbA1c and Reduces Weight in a 28-day Phase 1...
(Date:11/5/2009)...-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today...rter ended September 30, 2009. GenVec reported a n...three months ended September 30, 2009 compared to ...e comparable quarter of 2008. For the nine months ...4.1 million ($0.15 per share), compared to a net l...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
...versity,(SLU) recognized St. Louis-based Sigma-Ald...oring the life science and high technology company...onation, the third largest,in Sigma-Aldrich histor...equipment that will be used by the university,s me...newscom.com/cgi-bin/prnh/20071119/AQM157 ) "Sigma...
...peutics,Inc. (Nasdaq: CVTX ) announced today that...otified the Company that its supplemental new,drug... for Ranexa(R),(ranolazine extended- release table...iption Drug User Fee Act (PDUFA) action date for b... an expansion to the approved product labeling for...
...isk Inc.,announced today that it has signed an exc...t Prandin(R) (repaglinide). Under the terms of the...(R) and, upon approval by,the US Food and Drug Adm...DA for a repaglinide/metformin fixed dose combinat...ve a right of first refusal to obtain,marketing ri...
Other Biology Technology:Saint Louis University Honors Sigma-Aldrich Corp. for $1 Million Donation 2FDA Accepts Ranexa(R) sNDA and NDA for Filing 2FDA Accepts Ranexa(R) sNDA and NDA for Filing 3Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R) 2Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R) 3
(Date:11/9/2009)...ing Harbor, N.Y. Oncologists have had their hands...have mutations that disable a protein called p53. ...s several cancer-fighting operations within cells.... often cannot be treated. , These tumors might ...ew study from Cold Spring Harbor Laboratory (CSHL)...
(Date:11/9/2009)...illiance of butterfly wings has inspired a 3.2m, t...r innovation in the fields of security, energy and...ernational technology company QinetiQ have just si...ologies based on groundbreaking physical sciences ... physicists from the University of Exeter and Qine...
(Date:11/9/2009)...PHIA, NOVEMBER 9, 2009 A nutritionist whose rese...les to the federal Women, Infants and Children (WI...nes Higgins Award for outstanding achievement in t...arrison, Ph.D., MNS, , a professor in the Departme...of California, Los Angeles School of Public Health...
Breaking Biology News(10 mins):CSHL study shows that some malignant tumors can be shut down after all 2CSHL study shows that some malignant tumors can be shut down after all 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Target House 28R 29 Celebrates 10 Years with a Celebrity Studded Big Top Birthday Party 57062 1Target House 28R 29 Celebrates 10 Years with a Celebrity Studded Big Top Birthday Party 57062 2Target House 28R 29 Celebrates 10 Years with a Celebrity Studded Big Top Birthday Party 57062 3Target House 28R 29 Celebrates 10 Years with a Celebrity Studded Big Top Birthday Party 57062 4Target House 28R 29 Celebrates 10 Years with a Celebrity Studded Big Top Birthday Party 57062 5Target House 28R 29 Celebrates 10 Years with a Celebrity Studded Big Top Birthday Party 57062 6MWW Groups Washington D C Office Announces Two New Client Wins in Its Government Relations and Lobbying Practice 57057 1MWW Groups Washington D C Office Announces Two New Client Wins in Its Government Relations and Lobbying Practice 57057 2Vocollect and Boston Software Systems Announce Strategic Partnership 57054 1Vocollect and Boston Software Systems Announce Strategic Partnership 57054 2Vocollect and Boston Software Systems Announce Strategic Partnership 57054 3
...rominent scientific societies sponsored briefings ...anage natural areas after they have been impacted ...ociety of America (ESA), Council on Food, Agricult...nce Society of America (SSSA), the educational bri...ds of forest ecology, forest soil science and reso...
...t breed of supercomputers have hardware set up not...etworks of seemingly random data. And now, a multi...ed $4.0 million to develop software for these supe...webs of information can be found: from internet se...cal networks. , The difference between the new b...
...RELEASE , Detecting flu viruses in remote areas ...ociety , Researchers in Ohio and New Mexico are ...itive test to detect flu viruses one that require... of the world where new flu viruses often emerge. ... rather than antibodies, is in the July 2 issue of...
Other Biology News:Ecology, economics and soil societies brief Congress on post-wildfire resource management 2Multithreaded supercomputer seeks software for data-intensive computing 2Multithreaded supercomputer seeks software for data-intensive computing 3American Chemical Society's Weekly PressPac -- July 9, 2008 2American Chemical Society's Weekly PressPac -- July 9, 2008 3American Chemical Society's Weekly PressPac -- July 9, 2008 4American Chemical Society's Weekly PressPac -- July 9, 2008 5American Chemical Society's Weekly PressPac -- July 9, 2008 6American Chemical Society's Weekly PressPac -- July 9, 2008 7American Chemical Society's Weekly PressPac -- July 9, 2008 8American Chemical Society's Weekly PressPac -- July 9, 2008 9
Mouse Anti-Yersinia pestis Capsular F1 Antigen Monoclonal Antibody, Unconjugated, Clone YBF19 from QED Bioscience Inc.
Diethyl pyrocarbonate from Research Organics, Inc.
Cytofix Buffer from BD Biosciences Pharmingen
Cytofix/Cytoperm Kit from BD Biosciences Pharmingen
Biology Products: